EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> Orasis Pharmaceuticals closed a $13 million (€11 million) series B round. The Israeli biotech will use the money to take a treatment for presbyopia symptoms through a phase 2b trial. Statement

> Ali Mortazavi stepped down as CEO of Silence Therapeutics. Annalisa Jenkins, the former CEO of Dimension Therapeutics and current chair of Silence, will expand her role at the RNA specialist to cover for the loss of Mortazavi while a permanent replacement is sought. Release

> InflaRx opened a research facility in Ann Arbor, Michigan. The German biotech set up the facility to further its work on complement system-based therapeutics. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The FDA cleared Cellectis to trial its third off-the-shelf CAR-T therapy, UCART22, in patients with B-cell acute lymphoblastic leukemia. Release 

> Nanobiotix sought to reassure investors as its stock spiralled downward. Management at the French biotech said “no news or particular event, that would not have been disclosed to the public, has happened.” Statement 

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.